BR9902014A - Compostos peptìdicos que são análogos do peptìdio-1 (7-37) semelhante ao glucagon, processo para a preparação dos mesmos e composições farmacêuticas contendo os mesmos. - Google Patents

Compostos peptìdicos que são análogos do peptìdio-1 (7-37) semelhante ao glucagon, processo para a preparação dos mesmos e composições farmacêuticas contendo os mesmos.

Info

Publication number
BR9902014A
BR9902014A BR9902014-9A BR9902014A BR9902014A BR 9902014 A BR9902014 A BR 9902014A BR 9902014 A BR9902014 A BR 9902014A BR 9902014 A BR9902014 A BR 9902014A
Authority
BR
Brazil
Prior art keywords
peptide
group
gly
glucagon
pharmaceutical compositions
Prior art date
Application number
BR9902014-9A
Other languages
English (en)
Inventor
Bernard Calas
Gerard Grassy
Alain Chavanieu
Cyril Sarrauste De Menthiere
Pierre Renard
Bruno Pfeiffer
Dominique Manechez
Original Assignee
Adir
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adir filed Critical Adir
Publication of BR9902014A publication Critical patent/BR9902014A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Patente de Invenção: <B>"COMPOSTOS PEPTìDEOS QUE SãO ANáLOGOA DO PEPTìDEO-1 (7-37) SEMELHANTE AO GLUCAGON, PROCESSO PARA A PREPARAçãO DOS MESMOS E COMPOSIçõES FARMACêUTICAS CONTENDO OS MESMOS"<D>. Compostos peptídeos de fórmula (I): Z1-X~ 1~- X2-X3- Gly -Thr - Phe-Thr -Ser-X~ 4~-X~ 5~-Ser-X~ 6~-X~ 7~-X8-Glu-Gly-Gln-Ala-X~ 9~-Lys-X10-X~ 11~-X~ 12~-Ala_X13-X~ 14~-Val-Lys-Gly-X~ 15~-Gly-Z2 onde: .Z~ 1~, substituinte do grupo amino terminal, representa um átomo de hidrogênio ou um grupo alquila ou acila, ou um grupo arilcarbonila, heteroarilcarbonila, arialquicaronila, heteroarilcarbonila, ariloxicarbonila, arilalcoxicarbonila ou alcoxicarbonila, cada um deles sendo opcionalmente substituído, . Z2, substituinte do grupo carbonila terminal, representa um grupo hidróxi, um grupo alcóxi ou um grupo amino opcionalmente substituído, . Cada um de X1a X~ 14~ representa um resíduo de aminoácido tendo a configuração D ou L como definido no relatório descritivo, .X~ 15~representa uma ligação ou um resíduo arginina (Arg). Medicamentos.
BR9902014-9A 1998-04-10 1999-03-15 Compostos peptìdicos que são análogos do peptìdio-1 (7-37) semelhante ao glucagon, processo para a preparação dos mesmos e composições farmacêuticas contendo os mesmos. BR9902014A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9804559A FR2777283B1 (fr) 1998-04-10 1998-04-10 Nouveaux composes peptidiques analogues du glucagon-peptide- 1 (7-37), leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (1)

Publication Number Publication Date
BR9902014A true BR9902014A (pt) 2000-05-02

Family

ID=9525150

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9902014-9A BR9902014A (pt) 1998-04-10 1999-03-15 Compostos peptìdicos que são análogos do peptìdio-1 (7-37) semelhante ao glucagon, processo para a preparação dos mesmos e composições farmacêuticas contendo os mesmos.

Country Status (18)

Country Link
US (1) US6620910B1 (pt)
EP (1) EP0955314B1 (pt)
JP (1) JP3787242B2 (pt)
CN (1) CN1305897C (pt)
AT (1) ATE255596T1 (pt)
AU (1) AU761652B2 (pt)
BR (1) BR9902014A (pt)
CA (1) CA2263059A1 (pt)
DE (1) DE69913242T2 (pt)
DK (1) DK0955314T3 (pt)
ES (1) ES2212485T3 (pt)
FR (1) FR2777283B1 (pt)
HU (1) HUP9900604A3 (pt)
NO (1) NO323137B1 (pt)
NZ (1) NZ334379A (pt)
PL (1) PL331960A1 (pt)
PT (1) PT955314E (pt)
ZA (1) ZA992035B (pt)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
DE69922043T2 (de) * 1998-12-07 2005-11-24 Société de Conseils de Recherches et d'Applications Scientifiques S.A.S. Glp-1 analoge
JP2002538081A (ja) 1998-12-07 2002-11-12 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス Ｇｌｐ−１の類似体
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
US7186683B2 (en) 2000-09-18 2007-03-06 Sanos Bioscience A/S Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
US7371721B2 (en) 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
ES2310192T3 (es) * 2000-09-18 2009-01-01 Sanos Bioscience A/S Uso de peptidos glp-2.
GB0121709D0 (en) * 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
KR100989647B1 (ko) 2001-09-24 2010-10-26 오레곤 헬스 앤드 사이언스 유니버시티 식습관의 변화
US7238671B2 (en) 2001-10-18 2007-07-03 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
CA2463908A1 (en) 2001-10-18 2003-04-24 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
US7332819B2 (en) * 2002-01-09 2008-02-19 Micron Technology, Inc. Stacked die in die BGA package
US8058233B2 (en) * 2002-01-10 2011-11-15 Oregon Health And Science University Modification of feeding behavior using PYY and GLP-1
EP1474163A2 (en) 2002-01-10 2004-11-10 Imperial College Innovations Limited Modification of feeding behavior
US6923175B2 (en) 2002-03-20 2005-08-02 Mannkind Corporation Inhalation apparatus
US20080260838A1 (en) * 2003-08-01 2008-10-23 Mannkind Corporation Glucagon-like peptide 1 (glp-1) pharmaceutical formulations
GB0300571D0 (en) * 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
JP2007524579A (ja) * 2003-02-19 2007-08-30 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス Ｇｌｐ−１の類似体
US7550590B2 (en) 2003-03-25 2009-06-23 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7678909B1 (en) 2003-08-13 2010-03-16 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
KR20060041309A (ko) 2003-08-13 2006-05-11 다케다 야쿠힌 고교 가부시키가이샤 ４-피리미돈 유도체 및 펩티딜 펩티다제 저해제로서의 그의용도
US7790734B2 (en) 2003-09-08 2010-09-07 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
EP1711523B1 (en) * 2003-12-16 2012-10-10 Ipsen Pharma Analogues of glp-1
US7521527B2 (en) 2003-12-16 2009-04-21 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. GLP-1 pharmaceutical compositions
US7732446B1 (en) 2004-03-11 2010-06-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
CN102127057A (zh) 2004-03-15 2011-07-20 武田药品工业株式会社 二肽基肽酶抑制剂
JP2008501714A (ja) 2004-06-04 2008-01-24 武田薬品工業株式会社 ジペプチジルペプチダーゼインヒビター
WO2006019965A2 (en) 2004-07-16 2006-02-23 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
ATE486064T1 (de) 2004-08-20 2010-11-15 Mannkind Corp Katalyse der diketopiperazinsynthese
KR20130066695A (ko) 2004-08-23 2013-06-20 맨카인드 코포레이션 약물 전달용 디케토피페라진염, 디케토모르포린염 또는 디케토디옥산염
WO2006068978A2 (en) 2004-12-21 2006-06-29 Takeda Pharmaceutial Company Limited Dipeptidyl peptidase inhibitors
TW200643033A (en) * 2005-03-08 2006-12-16 Chugai Pharmaceutical Co Ltd Conjugate of water-soluble modified hyaluronic acid and glp-1 analogue
GB0511986D0 (en) * 2005-06-13 2005-07-20 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
MX373000B (es) 2005-09-14 2020-05-21 Mannkind Corp Metodo para formulacion de farmaco basado en el aumento de la afinidad de agentes activos hacia las superficies de microparticulas cristalinas.
GEP20135838B (en) 2005-09-14 2013-06-10 Takeda Pharmaceutical Dipeptidyl peptidase inhibitors usage at diabetes treatment
CN101360723A (zh) 2005-09-16 2009-02-04 武田药品工业株式会社 制备嘧啶二酮衍生物的方法
EP1943275B1 (en) * 2005-11-01 2010-06-16 Activotec SPP Limited Insulinotropic compounds and uses thereof
GB0522295D0 (en) * 2005-11-01 2005-12-07 Activotec Spp Ltd Peptides and uses thereof
EP1986679B1 (en) 2006-02-22 2017-10-25 MannKind Corporation A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
CN1982336B (zh) * 2006-03-03 2011-01-12 华东师范大学 一种人胰高血糖素样肽-1衍生物及其制备和应用
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
GB2448895A (en) * 2007-05-01 2008-11-05 Activotec Spp Ltd GLP-1 like compounds and uses thereof
EP2211842B1 (en) * 2007-10-24 2015-08-12 MannKind Corporation An inhalable dry powder formulation comprising glp-1 for use in the treatment of hyperglycemia and diabetes by pulmonary administration
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
CN101827626B (zh) 2008-06-13 2015-03-18 曼金德公司 干粉吸入器和用于药物输送的系统
ES2421385T3 (es) 2008-06-20 2013-09-02 Mannkind Corp Aparato interactivo y procedimiento para establecer el perfil, en tiempo real, de esfuerzos de inhalación
TWI532497B (zh) 2008-08-11 2016-05-11 曼凱公司 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
CN101463081B (zh) * 2009-01-12 2012-07-04 华东师范大学 一种glp-1衍生物
DK2405963T3 (da) 2009-03-11 2013-12-16 Mannkind Corp Apparat, system og fremgangsmåde til at måle modstand i en inhalator
WO2010120476A2 (en) * 2009-04-01 2010-10-21 Amylin Pharmaceuticals, Inc. N-terminus conformationally constrained glp-1 receptor agonist compounds
KR102584844B1 (ko) 2009-06-12 2023-10-04 맨카인드 코포레이션 한정된 비표면적을 갖는 디케토피페라진 마이크로입자
CA2778698A1 (en) 2009-11-03 2011-05-12 Mannkind Corporation An apparatus and method for simulating inhalation efforts
CN102985125A (zh) 2010-06-21 2013-03-20 曼金德公司 干粉药物输送系统和方法
CA2806749A1 (en) 2010-07-28 2012-02-02 Amylin Pharmaceuticals, Llc Glp-1 receptor agonist compounds having stabilized regions
SG194034A1 (en) 2011-04-01 2013-11-29 Mannkind Corp Blister package for pharmaceutical cartridges
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
MX2014004983A (es) 2011-10-24 2014-09-22 Mannkid Corp Metodos y composiciones para tratar dolor.
ES2810153T3 (es) * 2012-03-01 2021-03-08 Novo Nordisk As Profármacos de GLP-1
KR102264177B1 (ko) 2012-07-12 2021-06-11 맨카인드 코포레이션 건조 분말 약물 전달 시스템 및 방법
WO2014066856A1 (en) 2012-10-26 2014-05-01 Mannkind Corporation Inhalable influenza vaccine compositions and methods
EP3587404B1 (en) 2013-03-15 2022-07-13 MannKind Corporation Microcrystalline diketopiperazine compositions, methods for preparation and use thereof
MX375448B (es) 2013-07-18 2025-03-06 Mannkind Corp Composiciones farmacéuticas en polvo seco estables al calor y métodos.
EP3030294B1 (en) 2013-08-05 2020-10-07 MannKind Corporation Insufflation apparatus
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
RS63523B1 (sr) 2018-04-05 2022-09-30 Sun Pharmaceutical Ind Ltd Novi glp-1 analozi
CN110070918B (zh) * 2019-04-02 2022-12-27 重庆邮电大学 基于分子间相互作用的粗粒化方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE164852T1 (de) * 1990-01-24 1998-04-15 Douglas I Buckley Glp-1-analoga verwendbar in der diabetesbehandlung
US5545618A (en) * 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
SK155694A3 (en) * 1992-06-15 1995-05-10 Pfizer Glucagon-like peptide, insulinotropin derivatives, method of their preparation, pharmaceutical agent containing and using these matters
EP0658568A1 (en) * 1993-12-09 1995-06-21 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
US5705483A (en) * 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
WO1998043658A1 (en) * 1997-03-31 1998-10-08 Eli Lilly And Company Glucagon-like peptide-1 analogs

Also Published As

Publication number Publication date
JP3787242B2 (ja) 2006-06-21
CN1305897C (zh) 2007-03-21
CN1232038A (zh) 1999-10-20
PL331960A1 (en) 1999-10-11
PT955314E (pt) 2004-03-31
ES2212485T3 (es) 2004-07-16
ZA992035B (en) 1999-09-27
HUP9900604A2 (hu) 1999-09-28
DK0955314T3 (da) 2004-04-13
DE69913242T2 (de) 2004-09-09
US6620910B1 (en) 2003-09-16
ATE255596T1 (de) 2003-12-15
HU9900604D0 (en) 1999-05-28
CA2263059A1 (fr) 1999-10-10
JPH11310597A (ja) 1999-11-09
FR2777283B1 (fr) 2000-11-24
NO991199L (no) 1999-10-11
NZ334379A (en) 1999-10-28
EP0955314A2 (fr) 1999-11-10
EP0955314B1 (fr) 2003-12-03
NO991199D0 (no) 1999-03-11
AU761652B2 (en) 2003-06-05
AU2368899A (en) 1999-10-21
FR2777283A1 (fr) 1999-10-15
HK1022320A1 (en) 2000-08-04
DE69913242D1 (de) 2004-01-15
NO323137B1 (no) 2007-01-08
HUP9900604A3 (en) 2001-01-29
EP0955314A3 (fr) 2000-03-29

Similar Documents

Publication Publication Date Title
BR9902014A (pt) Compostos peptìdicos que são análogos do peptìdio-1 (7-37) semelhante ao glucagon, processo para a preparação dos mesmos e composições farmacêuticas contendo os mesmos.
ES2045017T3 (es) Derivado de benzotiazol, su utilizacion y compuestos farmaceuticos que lo comprenden.
BR9808593A (pt) Composições farmacêuticas com atividade supressora do apetite
BR9807824A (pt) Derivados de n-hidróxi-beta-sulfonil-propionamida e seu uso como inibidores de metaloproteinases de matriz
EP0511347A1 (de) Meta-substituierte phenylalanin-derivate
AR018634A1 (es) Derivados de benzo(b)tiepin-1,1,-dioxido, procedimiento para su preparacion, medicamentos conteniendo estos compuestos, procedimiento para la preparacion de medicamentos y su empleo para la preparacion de medicamentos.
RU93058379A (ru) Фармацевтическая композиция, содержащая определенную липидную систему, способ получения композиции и ее применение
BR9707064A (pt) Novos derivados 19-nor-pregneno
EP0810208A3 (en) N-substituted Hydroxyethylamino sulfamic acid derivatives useful as retroviral protease inhibitors
BR9916004A (pt) Inibidores de proteinase c de pró-colágeno
MX9300586A (es) Nuevos fragmentos de hormona paratiroidea proceso para su preparacion y composiciones farmaceuticas que los contienen.
BR0012478A (pt) Derivados de aminotiazóis, sua preparação e composição farmacêuticas contendo os mesmos
BR0309014A (pt) ácido(2-((2-alcóxi)-fenil)-ciclopent-1-enil)carbo e heterocìclico aromático e derivados
BR9813712A (pt) Derivados de n-fenilamida e n-piridilamida, método para preparação dos mesmos e composições farmacêuticas contendo os mesmos
BR9801448A (pt) Compostos heterocìclicos, processo para sua preparação e composições farmacêuticas contendo os mesmos.
BR9811954A (pt) ácidos 3-aril-succinamido-hidroxâmicos, processos para sua produção e preparações farmacêuticas contendo estas substâncias
AR035730A1 (es) Derivados de 2-arilamino-2,3-dihidrotiazol, composicion farmaceutica que lo comprende y su uso en la fabricacion de un medicamento
DK0966462T3 (da) Heterocykliske forbindelser, der er egnede som oxidosqualencyklaseinhibitorer
PT1218401E (pt) 4-benzilaminoquinolinas conjugadas com acido biliar e seus heterociclicos metodos de sua producao medicamentos contendo estes compostos e sua aplicacao
BR0005392A (pt) Composição de dhea e processo
BR9910020A (pt) Derivados do ácido octa-hidros-6,10-dioxo-6h-piridazino(1,2-a)(1,2)diazepi na-1-carboxìlico, seu processo de preparação e sua aplicação à preparação de compostos terapeuticamente ativos
BR0002679A (pt) Compostos de carboxilato de 7-oxo-2,3,7,14, tetraidro-1h-benzo[b]-pirano[3,2-h]acridina, processo para a sua preparação e composições farmacêuticas contendo os mesmos
EP0309971A3 (en) New spergualin-related compound and pharmaceutical composition
YU29299A (sh) Steroidi supstituisani u položaju 11, postupak njihovog dobijanja, njihova primena kod lekova i farmaceutski preparati koji ih sadrže
KR970705576A (ko) 페닐 펩티드, 이를 제조하는 방법, 및 이 펩티드를 함유하는 약제학적 조성물(phenyl peptides, method for preparing same, and pharmaceutical compositions containing said peptides)

Legal Events

Date Code Title Description
PC Transfer

Free format text: LES LABORATOIRES SERVIER (FR)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: PORTANTO, INDEFIRO O PRESENTE PEDIDO DE PATENTE COMO INVENCAO DE ACORDO COM OS ARTS. 8O, 13, 24 E 25 DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.